The trial showed a 'clinically meaningful' and 'statistically significant' improvement when treated with therapy plus BCG, ...

The investigational anti-PD-1 monoclonal antibody is showing positive topline results from the phase 3 CREST trial.

An FDA application for TAR-200 to treat BCG-unresponsive high-risk non-muscle-invasive bladder cancer is under real-time ...

If approved, Pfizer’s sasanlimab will distinguish itself from Merck’s blockbuster Keytruda as the first PD-1 inhibitor ...

Pfizer's experimental treatment for a type of bladder cancer significantly improved the time that patients remained free of ...

J&J acquired rights to TAR-200 when it bought privately-owned biotech Taris for an undisclosed sum in 2019, and has big sales ...

They were used on five patients, and four of them are now either in remission or cancer-free. Read more at straitstimes.com.

ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced significant progress in its ongoing ...

ImmunityBio, Inc. (NASDAQ:IBRX) released progress in its ongoing FDA discussions regarding three areas of its clinical ...

(RTTNews) - Johnson & Johnson (JNJ) Wednesday said it has initiated the submission of new drug application or NDA to Food and Drug Administration (FDA) for TAR-200 to treat patients with Bacillus ...

The antibody treatment, sasanlimab, in combination with Bacillus Calmette-Guérin (BCG) vaccine met the main goal of the study in patients with high-risk non-muscle invasive bladder cancer (NMIBC ...

Pfizer's Bladder Cancer Therapy Meets Main Goal in Late-Stage Study (Reuters) -Pfizer's experimental treatment for a type of bladder cancer significantly improved the time that patients remained ...